Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Lycera Corp.
Subjects who complete the 8 week treatment period of the double-blind, placebo-controlled study LYC-30937-2001 will have the option of receiving LYC-30397-EC 25 mg PO QD in this open-label extension study (LYC-30937-2002). Subjects meeting eligibility criteria will enter this open-label extension trial upon completion of the LYC-30937-2001 Week 8 study procedures. This open-label extension study will consist of 44 weeks of treatment followed by a 2 weeks post-treatment follow-up.
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Completed the 8-week double-blind treatment period of study LYC-30937-2001
Male and females of childbearing potential must agree to use adequate birth control during the study and for 30 days after discontinuing study drug
Non-pregnant, non-lactating females who are not planning to become pregnant while enrolled in this study
Investigator considers it safe and potentially beneficial to participate
Ability to provide written informed consent and to be compliant with study schedule
You may not be if
Subjects who completed study LYC-30937-2001, but who experienced a serious adverse event that was considered related to investigational product, has an unstable medical condition, or for any other reason in the opinion of the investigator should not participate in this study
